Seek Returns

RHHVF vs. UNH: A Head-to-Head Stock Comparison

Here’s a clear look at RHHVF and UNH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolRHHVFUNH
Company NameRoche Holding AGUnitedHealth Group Incorporated
CountrySwitzerlandUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesHealth Care Equipment & Services
GICS IndustryPharmaceuticalsHealth Care Providers & Services
GICS Sub-IndustryPharmaceuticalsManaged Health Care
Market Capitalization333.03 billion USD335.78 billion USD
CurrencyUSDUSD
ExchangeOTC Markets OTCQXNYSE
Listing DateFebruary 13, 2009October 17, 1984
Security TypeCommon StockCommon Stock

RHHVF’s market capitalization stands at 333.03 billion USD, while UNH’s is 335.78 billion USD, indicating their market valuations are broadly comparable.

Historical Performance

This chart compares the performance of RHHVF and UNH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

RHHVF
UNH
Loading price history…
RHHVF vs. UNH: Growth of a $10,000 investment over the past five years.

Historical Performance at a Glance

SymbolRHHVFUNH
5-Day Price Return1.16%0.26%
13-Week Price Return--34.00%
26-Week Price Return--7.25%
52-Week Price Return---5.45%
Month-to-Date Return1.16%-0.20%
Year-to-Date Return1.80%12.01%
10-Day Avg. Volume0.75M7.06M
3-Month Avg. Volume0.95M9.24M
3-Month Volatility--34.97%
Beta1.390.65

RHHVF’s beta of 1.39 points to significantly higher volatility compared to UNH (beta: 0.65), suggesting RHHVF has greater potential for both gains and losses relative to market movements.

Profitability

Return on Equity (TTM)

RHHVF

41.23%

Pharmaceuticals Industry
Max
41.64%
Q3
22.23%
Median
12.66%
Q1
5.01%
Min
-20.02%

In the upper quartile for the Pharmaceuticals industry, RHHVF’s Return on Equity of 41.23% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

UNH

12.40%

Health Care Providers & Services Industry
Max
30.14%
Q3
16.06%
Median
8.86%
Q1
6.67%
Min
-1.88%

UNH’s Return on Equity of 12.40% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

RHHVF vs. UNH: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Net Profit Margin (TTM)

RHHVF

13.68%

Pharmaceuticals Industry
Max
35.02%
Q3
18.94%
Median
13.68%
Q1
7.41%
Min
-8.35%

RHHVF’s Net Profit Margin of 13.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

UNH

2.68%

Health Care Providers & Services Industry
Max
11.23%
Q3
5.57%
Median
3.14%
Q1
1.10%
Min
-3.43%

UNH’s Net Profit Margin of 2.68% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

RHHVF vs. UNH: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Operating Profit Margin (TTM)

RHHVF

21.91%

Pharmaceuticals Industry
Max
43.63%
Q3
25.16%
Median
18.44%
Q1
10.95%
Min
-10.08%

RHHVF’s Operating Profit Margin of 21.91% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

UNH

4.12%

Health Care Providers & Services Industry
Max
18.14%
Q3
9.27%
Median
5.40%
Q1
2.06%
Min
-3.91%

UNH’s Operating Profit Margin of 4.12% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

RHHVF vs. UNH: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Profitability at a Glance

SymbolRHHVFUNH
Return on Equity (TTM)41.23%12.40%
Return on Assets (TTM)13.18%3.87%
Net Profit Margin (TTM)13.68%2.68%
Operating Profit Margin (TTM)21.91%4.12%
Gross Profit Margin (TTM)73.91%--

Financial Strength

Current Ratio (MRQ)

RHHVF

1.38

Pharmaceuticals Industry
Max
6.79
Q3
3.56
Median
2.01
Q1
1.38
Min
0.71

RHHVF’s Current Ratio of 1.38 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

UNH

0.89

Health Care Providers & Services Industry
Max
1.90
Q3
1.45
Median
1.24
Q1
0.91
Min
0.23

UNH’s Current Ratio of 0.89 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RHHVF vs. UNH: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

RHHVF

0.94

Pharmaceuticals Industry
Max
2.22
Q3
0.94
Median
0.29
Q1
0.06
Min
0.00

RHHVF’s Debt-to-Equity Ratio of 0.94 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

UNH

0.75

Health Care Providers & Services Industry
Max
2.35
Q3
1.29
Median
0.76
Q1
0.49
Min
0.00

UNH’s Debt-to-Equity Ratio of 0.75 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RHHVF vs. UNH: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Interest Coverage Ratio (TTM)

RHHVF

14.09

Pharmaceuticals Industry
Max
149.64
Q3
63.15
Median
13.00
Q1
2.46
Min
-27.02

RHHVF’s Interest Coverage Ratio of 14.09 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

UNH

4.67

Health Care Providers & Services Industry
Max
17.70
Q3
9.02
Median
5.30
Q1
2.65
Min
-6.68

UNH’s Interest Coverage Ratio of 4.67 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.

RHHVF vs. UNH: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Financial Strength at a Glance

SymbolRHHVFUNH
Current Ratio (MRQ)1.380.89
Quick Ratio (MRQ)1.120.67
Debt-to-Equity Ratio (MRQ)0.940.75
Interest Coverage Ratio (TTM)14.094.67

Growth

Revenue Growth

RHHVF vs. UNH: A comparison of their Revenue Growth across different time periods.

Revenue Growth at a Glance

SymbolRHHVFUNH
Revenue Growth (MRQ vs Prior YoY)5.91%1.96%
Revenue Growth (TTM vs Prior YoY)3.03%9.67%
3-Year Revenue CAGR-1.24%11.35%
5-Year Revenue CAGR-0.32%11.72%

EPS Growth

RHHVF vs. UNH: A comparison of their EPS Growth across different time periods.

EPS Growth at a Glance

SymbolRHHVFUNH
EPS Growth (MRQ vs Prior YoY)170.59%0.69%
EPS Growth (TTM vs Prior YoY)55.42%-44.58%
3-Year EPS CAGR1.43%-14.51%
5-Year EPS CAGR-0.60%-3.76%

Dividend

Dividend Yield (TTM)

RHHVF

3.26%

Pharmaceuticals Industry
Max
6.57%
Q3
3.20%
Median
2.07%
Q1
0.00%
Min
0.00%

With a Dividend Yield of 3.26%, RHHVF offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

UNH

2.40%

Health Care Providers & Services Industry
Max
5.59%
Q3
2.59%
Median
1.17%
Q1
0.00%
Min
0.00%

UNH’s Dividend Yield of 2.40% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.

RHHVF vs. UNH: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Dividend Payout Ratio (TTM)

RHHVF

65.10%

Pharmaceuticals Industry
Max
165.20%
Q3
80.25%
Median
44.79%
Q1
0.00%
Min
0.00%

RHHVF’s Dividend Payout Ratio of 65.10% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

UNH

66.50%

Health Care Providers & Services Industry
Max
187.56%
Q3
76.30%
Median
31.92%
Q1
0.00%
Min
0.00%

UNH’s Dividend Payout Ratio of 66.50% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RHHVF vs. UNH: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Dividend at a Glance

SymbolRHHVFUNH
Dividend Yield (TTM)3.26%2.40%
Dividend Payout Ratio (TTM)65.10%66.50%

Valuation

Price-to-Earnings Ratio (TTM)

RHHVF

19.96

Pharmaceuticals Industry
Max
47.94
Q3
27.38
Median
18.84
Q1
13.54
Min
3.85

RHHVF’s P/E Ratio of 19.96 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

UNH

27.70

Health Care Providers & Services Industry
Max
47.06
Q3
29.76
Median
20.85
Q1
14.64
Min
7.00

UNH’s P/E Ratio of 27.70 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RHHVF vs. UNH: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

RHHVF

4.25

Pharmaceuticals Industry
Max
9.09
Q3
4.81
Median
2.43
Q1
1.84
Min
0.20

RHHVF’s P/S Ratio of 4.25 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

UNH

0.74

Health Care Providers & Services Industry
Max
3.14
Q3
1.63
Median
0.75
Q1
0.28
Min
0.09

UNH’s P/S Ratio of 0.74 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RHHVF vs. UNH: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

RHHVF

--

Pharmaceuticals Industry
Max
10.12
Q3
5.17
Median
2.63
Q1
1.56
Min
0.63

P/B Ratio data for RHHVF is currently unavailable.

UNH

2.36

Health Care Providers & Services Industry
Max
9.26
Q3
5.24
Median
2.44
Q1
1.33
Min
0.63

UNH’s P/B Ratio of 2.36 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

RHHVF vs. UNH: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Health Care Providers & Services industry benchmarks.

Valuation at a Glance

SymbolRHHVFUNH
Price-to-Earnings Ratio (TTM)19.9627.70
Price-to-Sales Ratio (TTM)4.250.74
Price-to-Book Ratio (MRQ)--2.36
Price-to-Free Cash Flow Ratio (TTM)23.5716.90